Adherium Secures $2.6M to Advance Smart Inhaler in US
Filed with ASX · · 5 pages · English
Earlier from Adherium
- Management Change
- AstraZeneca selected Adherium Smartinhaler for its study
- Non-Renounceable Rights Issue Offer Completes
- Placement and Entitlement Offer to raise up to $8.37 million
- First Patient Enrolled in Major e-health Clinical Study
Later from Adherium
- $900K Capital Raise to Accelerate Smart Inhaler in US
- Accel Non-Renounceable Entitlement Offer to raise up to $4m
- Prospectus
- Successful Completion of Institutional Component of ANREO
- Replacement Prospectus
Follow Adherium into a list and get an email when it puts out news.
Follow Adherium